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ABSTRACT
Background: Cardiovascular Disease (CVD) is the number 1 leading cause of death in the
nation, even globally1. By 2030, the American Heart Association projects that 43.9% of
the US population will have some form of CVD2, with more than one-half of mortality
seen in the diabetic community3. Diabetic patients face increased inflammation, leading
to vascular complications; consequently, these patients may need small-caliber grafts.
Although the gold standard is represented by autologous blood vessels, these might be
affected by diabetes as well. Vascular tissue engineered grafts with the addition of
autologous adipose tissue-derived stem cells may be a promising alternative for these
patients, due to the immunomodulatory properties of these cells4.
Materials and Methods: a) Human adipose tissue-derived stem cells (hADSCs) and
human cardiac fibroblasts (hCFB) were co-cultured in transwell plates with human
macrophages, under high glucose conditions. After 7 days, cells were analyzed via
immunofluorescence for specific macrophage markers, CCR7 for type 1 (M1) and CD206
for type 2 (M2). b) Cell suspension of diabetic hADSCs/macrophages, diabetic
hCFBs/macrophages were injected into decellularized porcine renal arteries and
mounted into a vascular bioreactor for 7 days. Constructs were analyzed via Live/Dead
assay and immunohistochemistry for pan-macrophage marker (CD68), M1 (CCR7), and
M2 (CD206).
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Results and conclusions: Anti-inflammatory and pro-healing macrophages M2 were
present in both studies, demonstrating the promising immunomodulatory effect of
hADSCs in blood vessel tissue engineering.
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Part 1: INTRODUCTION
Chapter 1: Anatomy and Pathology of Cardiovascular and Vascular Systems
1.1.1 Introduction Cardiovascular Anatomy and Vascular Disease
Vascular disease (VD) is an encompassing medical term that refers to many
diseases such as atherosclerosis5, stiffening of blood vessels, hypertension5, affect
arteries and veins. VD leads to high levels of mortality and morbidity5. As VD progresses
it affects the functionality of blood vessels, as the conduits of the cardiovascular system
to create a gas and nutrient exchange to and from all sites of the body through blood
(Figure 1). The altering of blood vessels functionality creates a predisposition to the
heart becoming susceptible to myocardial infarction5.
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Figure 1 : Depiction of arteries and veins
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As seen in figure above, there are structural differences between arteries and
veins that leads to their functionality. Arteries, which are the focus in the progression of
VD, have well defined layers and differ in ratio to the heart (aorta’s tunica media is
thicker than a muscular artery).

1.1.2 Vascular Anatomy
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Figure 2 : Anatomy of blood vessels, red: artery and blue: vein

The vascular system is comprised of blood vessels with in the cardiovascular
system. The walls of blood vessels are made up of three layers, tunica intima, tunica
media, and tunica adventia (Figure 2). The tunica intima, the innermost layer of the
blood vessel, contains a layer of simple squamous endothelial cells and a basal
membrane. The tunica media is the medial layer of blood vessels and contains smooth
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muscle cells. It also contains elastic and collagen fibers. The outermost layer is the
tunica adventia, it is a sheath of loose areolar connective tissue with fibroblasts. Arteries
are differentiated as large or elastic arteries, muscular arteries, and arterioles. The
description of arteries is in the components of which they have, for example the content
of elastic fibers or more prominent medial layer. Muscular arteries have a distinct
internal elastic lamina, a thin sub endothelial layer of connective tissue, and external
elastic lamina, thick scalloped elastic fiber layer. Muscular arteries such as renal arteries
are used as scaffolds for small-caliber grafts due to their size and components.

1.1.3 Vascular Pathology
Through VD, there is a narrowing of the blood vessel, which may lead to
ischemia and hypoxia to further locations because of insufficient blood flow through the
affected areas. In other types of VD, there might be stiffening, which causes change in
blood pressure and laminar flow with in the blood vessels, creating environmental
changes for cells that cause endothelial dysfunction8 and vascular inflammation due to
vascular adventitia being activated early in vascular disease9.
VD may lead to debilitating or fatal outcomes such as myocardial infarctions
(heart attack) or cerebrovascular accident (stroke) through the travel of emboli to the
heart or the brain, respectively.
Many VDs are only managed through medical appointments with continuous
monitoring or drug therapies once detected until medical intervention is necessary, or
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the blood vessels get to a medically significant state, where physicians deduce the risk
of the surgery outweighs the risk of possible outcomes of advancement of the disease.
In this case intervention is the only way to manage the blood flow. The World Health
Organization (WHO) states that CVD is the number one leading cause of death
nationwide10. By 2030, 43.9% of the United States population is projected to have some
form of CVD2. This leads the American Heart Associated to predict that between 2012
and 2030 there will be a direct medical cost increase from $396 billion to $918 billion
due to CVD. This projection does not include indirect medical costs of CVD, such as
additional medications to treat ailments related to VD, life style adaptations due to VD,
nor ongoing research towards VD (prevention, treatment, surgeries). Even though VD
patients have these options, many with progressing VD continue to face surgical
intervention.
Treatments for VD after medical therapy lead to surgeries, such as minimally
invasive surgeries or invasive surgeries, in which the gold standard is to reduce the VD
presence at the site or replace blood vessels with autologous grafts (Figure 3). The
reduction of damage of the site of VD through surgery does not prevent the
continuation VD, it prolongs the viability of the blood vessel. The replacement of sites of
VD via an autologous graft lead to comorbidities and more often patients do not have
viable blood vessels to take from. The lack of autologous grafts is due to the way VD
progresses, if primary blood vessels are affected and are at the point of failure, smaller
blood vessels would be affected too. Which leads to another problem in VD – if the
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patient presents with the risk factors of VD (tobacco use5,8, diabetes5,8,11,12,
hypertension5,8,11) autologous grafts are less viable and surgery risks increase. For
example, in the diabetic community, CVD amounts for more than half of the mortality
seen with in the community3. In addition, most patients do not have enough viable
blood vessels due to systemic disease or advanced CVD (30% - 40%)13.

14

Figure 3 : Methods of CVD intervention specified by vascular substitute choice.

Currently, cardiovascular surgeons use balloon angioplasty, stents, and/or stent
grafts to prolong the viability of significantly obstructed. The methods seen in Figure 3
do not eradicate the VD at the surgery site; they increase the patency of the blood
vessels to medically acceptable percentage. Furthermore, if surgical intervention
becomes the only option for patients because the surgery does not cure VD; they are
likely to need further surgeries for the progression of VD.
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Chapter 2: EFFECTS OF DIABETES ON VASCULAR DISEASE
In conjunction with the rise of vascular, diabetes mellitus (diabetes), a systemic
disease, is projected to be the 7th leading cause of deaths in 20301 many of which relate
to the disease, as it cause underlying issues. In addition, the WHO “estimated 1.5 million
deaths were directly caused by diabetes, in 2012”15. Although there are many types of
diabetes, Type 1 and Type 2 are the most discussed. Type 13, also referred to as insulindependent or juvenile-onset, is an autoimmune response towards β-cells with in the
islets of Langerhans, in which they are destroyed, directly compromising the production
of insulin with in the patient. Type 2 diabetes3 is an overall resistance to insulin. This
type of diabetes has a high correlation with unhealthy lifestyles, such as poor diet16,17,
lack of exercise16,17, obesity

16, 17

, smoking16, and high cholesterol16. Specifically, in

patients with Type 2 diabetes, there are inconstant high or low concentrations of
glucose, especially if the disease is not regulated. At a point of high concentration of
glucose, the effects onto the blood vessel cannot be adverted as the patients are
resistant to their own insulin10.
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Figure 4 : Diabetes related hemodynamic, metabolic, and genetic changes

Diabetes increases the risk of VD due to the elevations of blood glucose levels
leading to the damage of blood vessels, such as microvascular complications3, including
angiopathy and cellular damage (Figure 4). For example, the adventitial fibroblast is the
“first-responder” to vascular injury, establishing the inflammatory response and
initiating the early disease development (adventitia becomes saturated with
inflammatory cells, primarily neutrophils and macrophages)9.
In addition, blood vessels in a diabetic environment tend stiffen due to different
factors such as the advanced glycation that occurs, advanced glycation can activate
common downstream pathways which contributes to fibrosis via excess accumulation of
extracellular matrix (ECM) proteins3. The stiffening of blood vessels is also due to the
calcification that occurs within.
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Figure 5 : AGEs introduction and consequence to the system

Advanced glycation occurs to free amino acid on protein groups and free amino
acids, called Maillard’s reaction. Maillard’s reaction is dependent on intracellular
glucose levels in the environment. An oversimplified purpose for the reaction is labeling
senescent cellular amino acids so they could be recognized and ultimate turnover3. But
as mentioned, advanced glycation has been seen to over stabilize ECM by causing a
crosslink between the proteins3, 18, 19,

20

. The persistence of high levels of glucose, as

seen in diabetes, increases advanced glycation end products (AGEs), causing
posttranslational modifications in both long-term and short-term proteins. AGEs can
influence many essential interactions such as matrix-matrix, cell-cell, or matrix-cell
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interactions. Figure 5 briefly explains the ultimate effects that AGEs can cause within
the system such as inflammation21, calcification11,22, dyslipidemia23, oxidative stress22,
arterial stiffening18,19, cardiac hypertrophy19. Furthermore, the chronic inflammation
recruits various types of cells, which continue to wreak havoc with in the already fragile
and altered system.

Chapter 3: INFLAMMATION, WITH RESPECT TO DIABETES
Inflammation is a natural response to injury, where there is infiltration of cells
and release of chemokines which eradicate any potential harm. Damage to blood
vessels due to diabetes leads to chronic inflammation, creating an overexposure to a
toxic environment, as the body cannot control nor heal these damages because of the
systemic disease. Tissue macrophages, mature monocytes, are the primary caretakers of
injury sites, once a disturbance is detected at a site, they phagocytize debris24, bacteria,
and kill intracellular pathogens25. Under macrophages there are two subsets, M1 and
M2, similar to Type 1 T helper (Th1) and Type 2 T helper (Th2), a “pro-inflammatory”
macrophage and an “anti-inflammatory” macrophage, respectively, which are
dependent on “cytokines and chemokines secreted by other cells within the
microenvironment”26,27. Polarization of macrophages from M1 to M2 is on a spectrum,
where the macrophages can have attributes from both. M1 macrophages are the
classical macrophage that cleans the site of injury and one of the main cells during
chronic inflammation. Specifically, M1 macrophages are present around implantations
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sites and continue to phagocytize or become Foreign Body Giant cells if there is a
biocompatibility issue and release inflammatory cytokines. Inflammatory cytokines such
as IL-12, interleukin associated with M1, create a necrotic environment that leads to the
destruction of neighboring tissue and cells. In the case of diabetes, the chronic
inflammation and deterioration of tissue can be attributed to an inflammatory response
due to the phagocytic response of inflammatory cells. On the other hand, the presence
of M2 macrophages is an optimistic sign that the host is remodeling, releasing antiinflammatory cytokines such as IL10 to recruit cells for angiogenesis. “M2 refers to
macrophages which are activated by interleukin-4 (IL-4), IL- 10, IL-13, or a combination
thereof, and possessing immunoregulatory or tissue remodeling characteristics which
include minimal production of pro-inflammatory molecules, expression of scavenger,
mannose, and galactose receptors, increased phagocytic activity, and participation in
polarized Th2 reactions.”

27

The potential to use the inflammatory process once the

polarization of M1/M2 macrophages is determined is promising for the resolution of
biological graft implantations. M1 and M2 macrophages can be identified through
various markers as shown in Figure 6, in addition CCR728 and CD20628 are markers that
can be present for M1 and M2 macrophages, respectively. To take advantage of the
polarization, immunomodulatory properties of potential cells must be assed, such as
human adipose derived stem cells (hADSCs).
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Figure 6 : Traditional markers of Macrophages (M1 – classical, M2- non-classical)

Chapter 4: IMMUNOMODULATORY EFFECTS OF HUMAN ADIPOSE DERIVED
STEMCELLS
Articles have hypothesized on the human adipose derived stem cells (hADSCs)
and their various properties, such as differentiation and immunomodulatory effects.
hADSCs are versatile and are readily available amongst patients and may be retrieved
through a minimally invasive method, such as liposuction, as they are derived from
adipose tissue. In addition, the yield of hADSCs does not have a statistical significant
difference when it comes to “gender or the presence of advanced age, obesity,
diabetes, end-stage renal or peripheral vascular disease”30. Although it has been seen
that in the in diabetic population, there is a slight decrease30 of hADSCs. hADSCs can
differentiate into the main types of cells seen in the vascular system, endothelial cells
and smooth muscle cells. In regards to the endothelial cell differentiation, hADSCs are
said to have a common progenitor that leads this differentiation31 and with the addition
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of specific growth medium that contains vascular endothelial growth factor (VEGF) and
human basic fibroblast growth factor (HBFGF) so differentiation occurs. In regards to
smooth muscle cell differentiation, TGFβ1 and bone morphogenic protein32, are used for
the differentiaton. Futhermore, hADSCs have an immunomodulatory effects by inducing
the release of angiogenesis-related mediators33 and mobilizing factors34. Previous work
of Dr. Chow’s26, in Clemson University, shows a primary investigation of the
immunomodulatory effects of autologous hADSCs on scaffold remodeling in diabetes –
demonstrating that acellular scaffolds seeded with hADSC allowed M2 polarization26.
This identification of potential cell populations leads to the use of the tissue engineering
paradigm.

Chapter 5: TISSUE ENGINEERING PARADIGM
“Tissue engineering is an interdisciplinary field that applies the principles of
engineering and the life sciences toward the development of biological substitutes that
restore, maintain or improve tissue function.”35 This definition explains the principle in
which biological scaffolds or synthetic scaffolds are used in a top-down or bottom-up36
approach, respectively. Figure 7 illustrates the method of a top-down approach in which
there is an isolation of specific cell types, such as stem cells, and re-cellularization of
decellularized scaffold which is combined for a functional construct. Scaffolds are
considered via their the macrostructure (the graft must be mechanically stable with
pore size large enough to physically let cells reside in, as well as allow for migration.),
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microstructure (the scaffold must induce cell attachment and allowing cells to generate
complex structures), and molecular structure (the scaffold must be able to release
molecules that induce specific cell responses)37.

38

Figure 7 : Overall Tissue Engineering Paradigm

The top-down approach uses native material in which the cellular content is
removed, while retaining components of the extracellular matrix (ECM). This reserves
the environment for cell attachment. In this manner, cell attachment can occur,
followed by cell integration into the scaffold. Once a scaffold is determined to be
decellularized, via histology, DNA quantification, and other methods of DNA
visiualization39, cells are seeded into scaffold, where cells are either differentiated into
specific cells or undifferentiated cells such as hADSCs. Cell seeding reintroduces
autologous cells into scaffold, in which they can recreate their native environment
whether through chemical stimuli or mechanical stimuli. Mechanical stimulation can be
achieved through bioreactors, systems which reenact biological environment such as
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pressure and flow rate that would be seen by native cells. The final product of the graft
is hypothesized to be a functional and viable alternative for patients, with low risk of
rejection due to autologous accommodations.

Chapter 6: PROJECT RATIONALE AND PROJECT AIMS

Aim 1:
Decellularization
of small diameter
artery

Aim 2: Cell-cell
interaction of
hADSCs and
macrophages

Aim 3: Bioreactor
study, cell
seeding under
diabetic
conditions

Figure 8: Linearization of each aim

The project aims are:
•

Aim 1: To develop a Blood Vessel Scaffold- Decellularization native renal artery to
create viable scaffold while maintaining the ECM components.

•

Aim 2: To assess macrophage polarization in the presence of stem cells and
fibroblasts- Interaction between hADSCs or human cardiac fibroblasts (hCFB) and
macrophages, MΦs, via co-cultures in high-glucose, referred to as diabetic,
conditions and normal conditions to investigate the polarization of MΦs in static
environment.

•

Aim 3: To study the mechanical conditioning on macrophage polarization in
Blood Vessel construct- Use of acellular scaffold and cell suspensions of hADSC or
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hCFB and MΦs inserted into a vascular bioreactor system in dynamic diabetic or
normal environments.
It is hypothesized that with the inclusion of hADSCs, the MΦs will polarized to M2
during a 7-day period in a diabetic environment, whether the environment is static or
dynamic.
In this project Aim 1 and Aim 2 products, decellularized scaffold and co-culture of
hADSCs, hCFB, and MΦs, are used in Aim 3. Decellularization of the biological scaffold
will be done and analyzed so no nuclear content is left behind without compromising
the structure of the ECM. Following the analysis of the decellularized scaffold, Aim 2 is
attained as the adequate number of specific cell types, hADSCs, hCFBs, and MΦs are
achieved. Aim 2 will be evaluated under two components – indirect co-culture of cells
and direct co-culture of cells within high glucose or normal conditions. The
determination of whether the MΦs polarize from pro-inflammatory M1 or antiinflammatory M2 through the presence of CCR7 or CD206, respectively. Finally Aim 3
will ascertain whether the dynamic environment of the vascular bioreactor induce the
same effect of MΦs as the static environment in Aim 2 did. Within Aim 2 and Aim 3,
normal and diabetic environments are considered.
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Part 2: RESEARCH METHODS, RESULTS, AND DISCUSSION

Chapter 1: MATERIALS AND METHODS OF AIMS
2.1.1 Preparation of Porcine Renal Arteries for Decellularization of Scaffolds.
2.1.1.1 Identification of Porcine Renal Artery
Porcine Kidneys were acquired from Snow Creek Meat Processing, Seneca, SC.
Once the porcine renal artery was identified, fascia and all fat were removed to further
view the artery. As excess material was removed, further branching of the renal artery
was visible. Slits were made on either side of pelvis of kidney to gain access to further
branches of the renal artery (Figure 9).

40

Figure 9 : Anatomy of kidney overview
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Once the smallest branches were visible, the fascia was removed and branches
were cut and removed from the kidney.

Figure 10: Fresh poricine renal artery with branches

Figure 10 displays cleaned and removed porcine renal artery branch from the
kidney. Potential segments, 1 cm long, were identified and retained for decellularization
process. Segments were stored overnight at 4°C, 3 segments per 100 mL of distilled
deionized water (ddH2O).

2.1.1.2 Decellularization of Porcine Renal Artery Segments
Segment of renal arteries, further referred to as scaffolds, were immersed in 0.1
M NaOH solution at a volume of 250 mL for 3 scaffolds. Once scaffolds were in NaOH
solution, they were placed in 37°C shaking water bath for 3 hours. Once the scaffolds
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were in NaOH for the allotted time, the arteries were rinsed 3 times in ddH2O at room
temperature for 30 minutes each time, allowing pH to fall to lower than 8. At the final
stage decellularization the water is decanted and replaced with 1X PBS.

Figure 11: Decellularized porcine renal artery, 1cm in length.

2.1.1.3 Sterilization of Decellularized Scaffolds
500 mL of peracetic acid solution, adjusted to a pH of 7.4, was vacuum filtrated.
Once the peracetic solution is sterilized, the decellularized scaffolds were placed in the
solution. The solution and scaffolds were agitated on an orbital shaker for 2 hours at
room temperature. Finally, the decellularized scaffolds were rinsed with sterile 1X PBS
for 30 minutes, with a total of 3 washes. The decellularized scaffolds were stored in
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sterile PBS at 4°C; 3 scaffolds were separated for decellularization analysis, through
histology, DNA quantification, and gel electrophoresis.

2.1.2 Cell-Cell Interaction Through Co-Culture
2.1.2.1. Indirect Co-culture of hADSC/hCFB and M#
Human blood MΦ were received from StemCell Technologies, Lot# 1501280266.
The MΦ were seeded onto the bottom of each well (Figure 12, A), at a concentration of
20,000 cells/well in a 6 well plate (from Corning) as per StemCell Technologies protocol
for preparation for use of MΦ. Once the MΦ were seeded, either high glucose
Dulbecco’s Modified Eagle Medium (DMEM) (4.5g glucose/L, 1% Antibiotic/Antimycotic,
10% Fetal Bovine Serum) or normal DMEM (1g glucose/L, 1% Antibiotic/Antimycotic,
10% Fetal Bovine Serum) added per the diagram in Figure 10 (Figure A), and incubated
for 30 minutes.
hADSCs and hCFB were cultivated in high glucose DMEM and normal DMEM. The
cells are further referred to as diabetic conditioned hADSC, diabetic conditioned hCFB,
normal conditioned hADSC, and normal conditioned hCFB, with respect in which DMEM
they were cultivated in for passage 15 (hADSC) and passage 13 (hCFB). Each condition
of cell was seeded unto the Transwell® Permeable Supports (from Corning), further
referred to as transwell membrane or membrane in their respective plates (Figure 12,
B).
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Figure 12: Co-culture experiment set up with transwell membrane plates. Figure A: Depiction of Side view of
transwell membrane. Figure B: Depiction of 6-well plate set up with time points.

Figure 13: Time points for cell lysate and media extraction.

At each time point, depicted in Figure 13, cell lysates on the bottom of the plate
were acquired and further analyzed, while the cells on the membrane were fixed in
paraformaldehyde. At TP 3, media was recovered for remaining wells and replaced for
wells for TP 4 and TP 5. Similarly, at TP 4, media was recovered for the remaining wells
and replaced for wells for TP 7. All media that was recovered was stored at -20°C. Figure
14 further illustrates 6-well plate set up with corresponding time points. Final wells in
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each 6-well plate were fixed in paraformaldehyde and analyzed through
immunofluorescence.

Figure 14: Indirect co-culture experiment set up, with corresponding media.

2.1.2.2 Direct Co-culture of hADSC/hCFB and M#
After injected scaffolds (further explained in the following section) remained in
static conditions overnight, cells seeped from the scaffold into their respective well. This
instance created a direct co-culture of hADSCs and MΦ and hCFB and MΦ in their
respective DMEM conditions depicted in Figure 15.
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Figure 15: Direct co-culture experiment set up

Media was recovered after 3 days and 6 days of initial attachment and stored in
at -20°C. After 7 days of initial attachment, cells were fixed in paraformaldehyde and
prepared for immunofluorescence.

2.1.3 Normal and Diabetic Bioreactor Experiment
Cells were suspended in either high glucose DMEM or normal DMEM and
separated as per their combination: diabetic conditioned hADSC and MΦ, diabetic
conditioned hCFB and MΦ, normal conditioned hADSC and MΦ, and normal
conditioned hCFB and MΦ.
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Figure 16: Overall setup of bioreactor experiment

Cell suspension was injected transversely through each scaffold, removing the
needle slowly while depressing the plunger. Scaffolds were placed in wells, depicted in
Figure 15, and were incubated for overnight in static conditions. A general depiction of
the rest of the bioreactor study is depicted in Figure 16.
DMEM was made for each condition with 2% Antibiotic/Antimycotic, 20% Fetal
Bovine Serum and either 4.5 g glucose/L (for diabetic conditioned) or 1 g glucose/L (for
normal conditioned).
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Figure 17: General bioreactor set up

After the incubation period of the scaffolds, the bioreactors (BR) were set up.
Each bioreactor was constructed as depicted in Figure 17, diabetic conditioned
bioreactor and normal conditioned bioreactor. Once tubes were connected to media
reservoirs, manifolds, and the chamber and it was ascertained that the media loop was
closed; half of the DMEM was added to the closed cap media reservoir. At this point the
system was checked for any leaks. The scaffolds were then cannulated and secured with
sutures into the chamber of the bioreactor. The chamber was then closed and screws
were fastened and the remaining media was added into the system via the sealed cap
media reservoir and sealed. Each bioreactor was set into the incubator, as depicted in
Figure 18A, with the peristaltic pump, initially set at 50mL/hour.
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Figure 18: Figure A: Bioreactor set up with in incubator, Figure B: Bioreactor once it was removed from incubator
on day 7

After 12 hours, after setting the bioreactors in the incubator, the peristaltic
pump was set at 150 mL/hr, and finally at 24 hours, the peristaltic pump was set to 250
mL/hr until the end of the 7-day period. The bioreactor systems were checked daily. At
day 7, the scaffolds were removed and dissected for live/dead analysis and histological
analysis.
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Chapter 2: EXPERIMENTAL RESULTS
2.2.1. Experimental Results of Decellularization of Scaffolds
2.2.1.1 Histological Analysis

Figure 19: Histological analysis- Top row, Fresh. Bottom row, decellularized scaffold. Stains were Hematoxylin and
Eosin (H&E) – dark purple, nuclei; pink, cytoplasm, DAPI – fluorescent blue, nuclei, Masson’s Trichrome – blue,
collagen; red, muscle fibers, dark brown/black - nuclei.

Decellularization of scaffolds were analyzed via histology, DNA quantification,
and Gel Electrophoresis. H&E of decellularized scaffold showed cytoplasm was intact
and there were no visible nuclei, Figure 19. DAPI showed that no nuclei fluoresced in
decellularized scaffold, Figure 19. Via the Masson’s Trichrome Stain Figure 19, no nuclei
were seen but the collagen and muscle fibers unaltered.
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DNA Concentration (ng DNA/mg Tissue
Wet Weight)

2.2.1.2 DNA Quantification

DNA Quantification Between Fresh and
Decellularized Tissue
183.59

200.00
150.00
100.00
50.00

7.81 *

Decellularized Scaffold

Fresh Artery

Figure 20: DNA quantification between Fresh Renal Artery and Decellularized Scaffold, (*) signifies there is a
statistical difference between fresh artery and decellularized scaffold.

DNA quantification Figure 20 via Nanodrop demonstrated that there was a
statistical difference (t-test was evaluated, p= 1.99159E-12) between the fresh artery
and decellularized scaffold.
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2.2.1.3 Gel Electrophoresis

st

th

Figure 21: Gel Electrophoresis of Fresh, 1 through 6 trial of Decellularized Scaffold. Kaleidoscope DNA Ladder in
st
rd
th
1 lane, Fresh Artery in 3 and 4 Lanes, Decellularized scaffolds in remaining lanes.

Finally, through imaging of the electrophoresis gel Figure 21, DNA fragments
were seen in specimen representing first round of scaffold of decellularization, but no
other content was seen for the other specimens of decellularization.
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2.2.2. Results of Indirect Co-Culture, MΦ
2.2.2.1. Immunofluorescence

Figure 22: Immunofluorescence images of macrophages on Day 7 of Diabetic hADSC transwell plate. CCR7
fluoresced green, M1 marker, Left column. CD206 fluoresced red, M2 marker, Middle column. Cells identified by
outlining of respective color. Overlay of CCR7/CD206 images displayed in right column.

Immunofluorescence of samples Figure 22 demonstrated the presence of M1
and M2 markers. The overlay displayed a prominence of M1 marker in the Diabetic
conditioned hADSC plate.
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Figure 23: Immunofluorescence images of macrophages on Day 7 of Diabetic hCFB transwell plate. CCR7 fluoresced
green, M1 marker, Left column. CD206 fluoresced red, M2 marker, Middle column. Cells identified by outlining of
respective color. Overlay of CCR7/CD206 images displayed in right column.

Immunofluorescence of samples Figure 23 demonstrated the presence of M1
and M2 markers. The overlay displayed a prominence of M1 marker in the Diabetic
conditioned hCFB plate. Figure 23, the well with hCFB on transwell membrane showed
clusters of cells.
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Figure 24: Immunofluorescence images of macrophages on Day 7 of Normal hADSC transwell plate. CCR7
fluoresced green, M1 marker, Left column. CD206 fluoresced red, M2 marker, Middle column. Cells identified by
outlining of respective color. Overlay of CCR7/CD206 images displayed in right column.

Immunofluorescence of samples Figure 24 demonstrated the presence of M1
and M2 markers. The top overlay displayed a prominence of M2 marker, while bottom
overlay displayed prominence of M1 marker in the Normal conditioned hADSC plate.
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Figure 25: Immunofluorescence images of macrophages on Day 7 of Normal hCFB transwell plate. CCR7 fluoresced
green, M1 marker, Left column. CD206 fluoresced red, M2 marker, Middle column. Cells identified by outlining of
respective color. Overlay of CCR7/CD206 images displayed in right column.

Immunofluorescence of samples Figure 25 demonstrated the presence of M1
and M2 markers. The overlay displayed a prominence of M1 marker in the Normal
conditioned hCFB plate. Figure 25, the well with hCFB on transwell membrane showed
clusters of cells.
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2.2.3. Experimental Results of Direct Co-Culture and Corresponding Cells
2.2.3.1. Immunofluorescence

Figure 26: Immunofluorescence images of macrophages and hADSC on Day 7 of Diabetic hADSC well. CCR7
fluoresced green, M1 marker, Left column. CD206 fluoresced red, M2 marker, Middle column. Cells identified by
outlining of respective color. Overlay of CCR7/CD206 images displayed in right column.

Immunofluorescence of samples Figure 26 demonstrated the presence of M1
and M2 markers. The overlay displayed a prominence of M2 marker in the Diabetic
conditioned hADSC/MΦ direct co-culture, and a difference characteristic in nuclei than
seen in prior co-culture. Nuclei in overlay are larger, with dark spots towards the inner
part of the imaged nuclei.
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Figure 27: Immunofluorescence images of macrophages and hCFB on Day 7 of Diabetic hCFB well. CCR7 fluoresced
green, M1 marker, Left column. CD206 fluoresced red, M2 marker, Middle column. Cells identified by outlining of
respective color. Overlay of CCR7/CD206 images displayed in right column.

Immunofluorescence of samples Figure 27 demonstrated the presence of M1
and M2 markers. The overlay displayed a prominence of M2 marker in the Diabetic
conditioned hCFB/MΦ direct co-culture.
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Figure 28: Immunofluorescence images of macrophages and hADSC on Day 7 of Normal hADSC well. CCR7
fluoresced green, M1 marker, Left column. CD206 fluoresced red, M2 marker, Middle column. Cells identified by
outlining of respective color. Overlay of CCR7/CD206 images displayed in right column.

Immunofluorescence of samples Figure 28 demonstrated the presence of M1
and M2 markers. The overlay displayed a prominence of M2 marker in the Normal
conditioned hADSC/MΦ direct co-culture and a difference characteristic in nuclei than
seen in prior co-culture. Nuclei in overlay are larger, with dark spots towards the inner
part of the imaged nuclei. In addition, there were prominent clusters with in the sample.
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Figure 29: Immunofluorescence images of macrophages and hCFB on Day 7 of Normal hCFB well. CCR7 fluoresced
green, M1 marker, Left column. CD206 fluoresced red, M2 marker, Middle column. Cells identified by outlining of
respective color. Overlay of CCR7/CD206 images displayed in right column.

Immunofluorescence of samples Figure 29 demonstrated the presence of M1
and M2 markers. The overlay displayed a prominence of M2 marker in the Normal
conditioned hCFB/MΦ direct co-culture and a difference characteristic in nuclei than
seen in prior co-culture. Nuclei in overlay are larger, with dark spots towards the inner
part of the imaged nuclei. In addition, there were prominent clusters with in the sample.
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2.2. 4.. Bioreactor Study of Scaffolds with Corresponding Cells
2.2.4.1. Live/Dead Assay

Figure 30: Images of Live/Dead assay of scaffolds, Green: Live cells, Red: Dead cells.

Live/Dead assay were imaged with a ring of scaffold in the middle of scaffold.
Images representatively showed there was a low cell attachment onto scaffolds.
Although in hADSC scaffolds live cells were visible in images shown in Figure 30.
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2.2.4.2. Immunohistochemistry

Figure 31: Immunohistochemistry of scaffolds. Negative control, no primary antibody was used. Images of CD68
positive, CCR7 positive, and CD206 positive were enlarged. Images in the corner of each image displays where the
enlargement occurred.

In immunohistochemistry images Figure 31, CCR7 was prevalent in all scaffolds
except Normal hCFB and MΦ; CD68 (pan- MΦ marker) and CD206 was not visible in any
of scaffolds.
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Part 3: DISCUSSION AND CONCLUSIONS OF AIMS, FUTURE WORK
Decellularization of scaffolds were achieved – no nuclear content was seen via
H&E nor DAPI. In addition, no DNA fragments were seen in gel electrophoresis.
Furthermore, there was a statistical difference in DNA quantification between fresh
renal arteries and decellularized scaffold. This lead to a reduction of DNA from fresh
artery to decellularized scaffold of 95.74%. Structure of collagen and muscle fibers were
compared between fresh arteries and decellularized scaffolds via Masson’s Trichrome,
concluding that there was no difference in the presence of either. Conclusion of the
decellularization of scaffolds was complete, with a no structural difference between the
native renal artery and the scaffold.
Cell interaction studies of diabetic and normal environment in static conditions
displayed a presence of CCR7 and CD206, markers chosen to identify M1 and M2
macrophages respectively. In the direct co-culture of MΦ and hADSCs or hCFB, there
was a more prominent fluorescence of M2 markers than that of the indirect co-culture.
Bioreactor study showed there was a lack of cell attachment onto the scaffolds. This
may have occurred due to cell seeding method of injection. Cell suspension injection
lead to leakage of cells onto wells where the scaffolds remained in overnight. This
leakage of cells caused an undetermined number of cells to remain on the scaffolds
prior to being placed in vascular bioreactor apparatus. In addition, the injection method
caused damage to scaffold where the perforation of needle occurred. Following the
analysis through immunohistochemistry, CCR7 was positive in all scaffolds except the
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normal hCFB scaffold. The pan-MΦ marker was not seen in any of the scaffolds –
leading to an inconclusive reasoning of CCR7 presence on the scaffold.
The aim to develop a blood vessel scaffold, was achieved as cellular content was
removed while containing the structural content of the scaffold comparable to the fresh
artery. While assessing the polarization of macrophages in co-culture of hADSC and
hCFB, there were no visible difference in the amount of polarization of macrophages in
the co-cultures. In addition, there was no significant difference between normal and
diabetic conditions seen in the in-vitro cultures, nor the dynamic conditions. In the
dynamic conditions of the scaffold with in the vascular bioreactor, there was a presence
of M1 marker, but no other markers for macrophages with in the scaffolds in normal
and diabetic conditions.
Future work would include analysis of all media samples retained through coculture experiments to determine cytokines were released through time points
observed. This would lead to distinguish differences between direct and indirect cocultures. As per the bioreactor study, a new cell seeding method must be determined.
Most promising would be the inclusion of a gel for the cell seeding method. The gel
would create a matrix in which the cells can continue to suspend in until cell attachment
onto the scaffolds would occur. The inclusion of the gel would also avoid the leakage of
cell suspension, making a more reliable retention of cells onto the scaffold. In addition,
pilot studies should be done to determine how mechanical stimuli – such as flow –
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affects the polarization of macrophages. Finally, an in-vivo study of macrophage
polarization would yield prospective results on the effects of diabetes on macrophages.
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APPENDIX
A.1. Original Indirect Immunofluorescence Images

Figure A: Original immunofluorescence images of macrophages on Day 7 of Diabetic hADSC transwell plate. CCR7
fluoresced green, M1 marker, Left column. CD206 fluoresced red, M2 marker, Middle column. Overlay of
CCR7/CD206 images displayed in right column.
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Figure B: Original immunofluorescence images of macrophages on Day 7 of Diabetic hCFB transwell plate. CCR7
fluoresced green, M1 marker, Left column. CD206 fluoresced red, M2 marker, Middle column. Overlay of
CCR7/CD206 images displayed in right column.
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Figure C: Original immunofluorescence images of macrophages on Day 7 of Normal hADSC transwell plate. CCR7
fluoresced green, M1 marker, Left column. CD206 fluoresced red, M2 marker, Middle column. Overlay of
CCR7/CD206 images displayed in right column.

Figure D: Original immunofluorescence images of macrophages on Day 7 of Normal hCFB transwell plate. CCR7
fluoresced green, M1 marker, Left column. CD206 fluoresced red, M2 marker, Middle column. Overlay of
CCR7/CD206 images displayed in right column.
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A.2. Original Direct Immunofluorescence Images

Figure E: Original immunofluorescence images of macrophages and hADSC on Day 7 of Diabetic hADSC well. CCR7
fluoresced green, M1 marker, Left column. CD206 fluoresced red, M2 marker, Middle column. Overlay of
CCR7/CD206
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Figure F: Original immunofluorescence images of macrophages and hCFB on Day 7 of Diabetic hCFB well. CCR7
fluoresced green, M1 marker, Left column. CD206 fluoresced red, M2 marker, Middle column. Overlay of
CCR7/CD206

Figure G: Original immunofluorescence images of macrophages and hADSC on Day 7 of Normal hADSC well. CCR7
fluoresced green, M1 marker, Left column. CD206 fluoresced red, M2 marker, Middle column. Overlay of
CCR7/CD206
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Figure H: Original immunofluorescence images of macrophages and hCFB on Day 7 of Normal hCFB well. CCR7
fluoresced green, M1 marker, Left column. CD206 fluoresced red, M2 marker, Middle column. Overlay of
CCR7/CD206
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